The short version
10 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
pomalidomide · POMALIDOMIDE 2 mg/1 · Capsule · Oral · Sandoz Inc
NDC 00781-2358-27 · 21 CAPSULE in 1 BOTTLE · ANDA · View full market →
10 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 59572-0502-21) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Cipla USA Inc. | POMALIDOMIDE 2 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Cipla USA Inc. | POMALIDOMIDE 3 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Cipla USA Inc. | POMALIDOMIDE 4 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Cipla USA Inc. | POMALIDOMIDE 1 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Dr. Reddy's Laboratories Inc. | POMALIDOMIDE 1 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Dr. Reddy's Laboratories Inc. | POMALIDOMIDE 2 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Dr. Reddy's Laboratories Inc. | POMALIDOMIDE 4 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Dr. Reddy's Laboratories Inc. | POMALIDOMIDE 3 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Sandoz Inc | POMALIDOMIDE 1 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Sandoz Inc | POMALIDOMIDE 3 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Sandoz Inc | POMALIDOMIDE 2 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Sandoz Inc | POMALIDOMIDE 4 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Sun Pharmaceutical Industries, Inc. | POMALIDOMIDE 3 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Sun Pharmaceutical Industries, Inc. | POMALIDOMIDE 1 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Sun Pharmaceutical Industries, Inc. | POMALIDOMIDE 4 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Sun Pharmaceutical Industries, Inc. | POMALIDOMIDE 2 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
| Apotex Corp. | POMALIDOMIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Apotex Corp. | POMALIDOMIDE 1 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Apotex Corp. | POMALIDOMIDE 3 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Apotex Corp. | POMALIDOMIDE 4 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | POMALIDOMIDE 3 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | POMALIDOMIDE 1 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | POMALIDOMIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | POMALIDOMIDE 4 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Breckenridge Pharmaceutical, Inc. | POMALIDOMIDE 1 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Breckenridge Pharmaceutical, Inc. | POMALIDOMIDE 4 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Breckenridge Pharmaceutical, Inc. | POMALIDOMIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Breckenridge Pharmaceutical, Inc. | POMALIDOMIDE 3 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | POMALIDOMIDE 3 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | POMALIDOMIDE 1 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | POMALIDOMIDE 4 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | POMALIDOMIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Celgene Corporation | POMALIDOMIDE 4 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Celgene Corporation | POMALIDOMIDE 3 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Celgene Corporation | POMALIDOMIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Celgene Corporation | POMALIDOMIDE 1 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Natco Pharma Limited | POMALIDOMIDE 3 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Natco Pharma Limited | POMALIDOMIDE 4 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Natco Pharma Limited | POMALIDOMIDE 1 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Natco Pharma Limited | POMALIDOMIDE 2 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Pomalidomide — NDC 00781-2358-27," retrieved September 3, 2026, https://drugdashboards.com/drug/00781235827.
Free to cite with attribution — see how the data is put together.